Items where authors include "Alani, M"

Export as [feed] Atom [feed] RSS
Number of items: 9.

Conference or Workshop Item

Mease, PJ, Coates, LC, Van den Bosch, F et al. (8 more authors) (2021) Correlation Between Skin Involvement, Joint Involvement and Enthesitis in Patients with Active Psoriatic Arthritis: Post-hoc Analysis of EQUATOR/EQUATOR2. In: EULAR 2021 Virtual Congress (Rheumatology), 02-05 Jun 2021, Virtual.

Helliwell, P orcid.org/0000-0002-4155-9105, Coates, LC, Van den Bosch, F et al. (7 more authors) (2021) The Effect of Filgotinib on Enthesitis: 100-Week Data from an Open-Label Extension Study in Patients with Active Psoriatic Arthritis. In: EULAR 2021 Virtual Congress (Rheumatology), 02-05 Jun 2021, Virtual.

Coates, LC, Mease, PJ, Helliwell, P orcid.org/0000-0002-4155-9105 et al. (8 more authors) (2021) Effect of Filgotinib on Pasdas: Drivers of Low and Very Low Activity up to Week 100. In: EULAR 2021 Virtual Congress (Rheumatology), 02-05 Jun 2021, Virtual.

Coates, LC, Gladman, DD, Van den Bosch, F et al. (10 more authors) (2021) Long-Term Outcomes with Filgotinib, an Oral Preferential Janus Kinase 1 Inhibitor: 100-Week Data from an Open-Label Extension (OLE) Study in Patients with PSA. In: Twelfth International Congress on Spondyloarthritides, 09-11 Sep 2021, Virtual.

Mease, P, Coates, L, Van den Bosch, F et al. (7 more authors) (2020) Effect of Filgotinib on the Complete Resolution of Enthesitis in Psoriatic Arthritis (PsA) Patients: 52-week Results from EQUATOR2. In: ACR Convergence 2020, 05-09 Nov 2020, Virtual.

Coates, L, Gladman, D, Van den Bosch, F et al. (10 more authors) (2020) Long-term Outcomes with Filgotinib, an Oral Selective Janus Kinase 1 Inhibitor: 100-week Data from an Open-label Extension (OLE) Study in Patients with Active Psoriatic Arthritis (PsA). In: ACR Convergence 2020, 05-09 Nov 2020, Virtual.

Gladman, DD, Coates, LC, Van den Bosch, F et al. (9 more authors) (2020) FRI0339 LONG-TERM EFFICACY OF THE ORAL SELECTIVE JANUS KINASE 1 INHIBITOR FILGOTINIB IN PSORIATIC ARTHRITIS: WEEK 52 RESPONSE PATTERNS IN INDIVIDUAL PATIENTS FROM AN OPEN-LABEL EXTENSION (OLE) STUDY (EQUATOR2). In: EULAR 2020, 03-06 Jun 2020, Online.

Helliwell, P, Van den Bosch, F, Coates, LC et al. (9 more authors) (2020) FRI0343 EFFICACY AND SAFETY OF FILGOTINIB, A SELECTIVE JANUS KINASE 1 INHIBITOR, IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: SUBGROUP ANALYSES FROM A RANDOMIZED, PLACEBO-CONTROLLED, PHASE 2 TRIAL (EQUATOR). In: EULAR 2020, 03-06 Jun 2020, Online.

Husni, ME, Gladman, DD, Helliwell, P et al. (9 more authors) (2020) FRI0344 THE LONG-TERM EFFECT OF TREATING PSORIATIC ARTHRITIS WITH THE JANUS KINASE 1-SELECTIVE INHIBITOR FILGOTINIB ON LIPID PROFILES: AN ANALYSIS OF THE EQUATOR AND EQUATOR2 TRIALS. In: EULAR 2020, 03-06 Jun 2020, Online.

This list was generated on Sat Mar 23 03:52:28 2024 GMT.